extra credit - patients in the experimental drug group so...

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
Nicole Safiano Clinical Trial Argument Extra Credit (P1) Act so as to promote the welfare of others (beneficence). (P2) Act so as to prevent needless harm to others (nonmaleficence). (P3) Never use a person as a means to an end (Kantian autonomy). (P4) All rational individuals should be permitted to be self-determing (autonomy). (P5) Any clinical trial should uphold P1-P4 and be adopted. (P6) Dr. Kelley’s scenario (clinical trial) would uphold P1-P4 if it had the following features: (P6a) Dr. Kelley’s patients should be given proper informed consent including the probability of being placed in the experimental and placebo group and the current success rate yielded. (autonomy) (P6b) Dr. Kelley suspects an 80% success rate for the experimental drug and should enroll more
Background image of page 1
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: patients in the experimental drug group so as to provide more potential good for more patients (beneficence). (P6c) Dr. Kelley should enroll less patients (perhaps 1:10) in the placebo group so as to prevent harm to less patients by them not receiving any treatment (nonmaleficence). (P7) A clinical trial that does not uphold P1-P4 should be rejected. (P8) The clinical trial scenario would not uphold P1-P4 if it had the following features: (P8a) The same amount of patients should not continue to be enrolled in the experimental and placebo groups, given the expected success rate (violating Kantian autonomy). Therefore, Dr. Kelley ought to implement the system for clinical trials described in P6....
View Full Document

This note was uploaded on 06/15/2011 for the course PHL 116 taught by Professor Sullivan during the Fall '09 term at University of Alabama at Birmingham.

Ask a homework question - tutors are online